Status:
ACTIVE_NOT_RECRUITING
Zephyr Etude Post-Inscription (French Registry)
Lead Sponsor:
Pulmonx Corporation
Conditions:
Emphysema or COPD
Eligibility:
All Genders
Brief Summary
The objective of this Registry is to provide ongoing safety and effectiveness assessment of the Zephyr Valve treatment of adult patients with Chronic Obstructive Pulmonary Disease (COPD) Grade III and...
Detailed Description
This is a multi-center, single-arm, prospective Registry to be conducted at a minimum of 12 study centers. Approximately 150 patients with severe emphysema undergoing Zephyr Valve treatment will be en...
Eligibility Criteria
Inclusion
- Patients with emphysema (COPD Grade III and Grade IV) considered appropriate for the bronchoscopic lung volume reduction procedure by the physician.
- Subjects who signed an Informed Consent Form to allow data collection.
Exclusion
- Subjects determined to have collateral ventilation between the target(s) and ipsilateral lobe(s).
Key Trial Info
Start Date :
January 4 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 30 2025
Estimated Enrollment :
155 Patients enrolled
Trial Details
Trial ID
NCT04517916
Start Date
January 4 2021
End Date
September 30 2025
Last Update
April 29 2025
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital La Cavale Blanche
Brest, France
2
Hôpital François Mitterrand
Dijon, France
3
Hôpital Nord
Latronche, France
4
Hôpital Calmette
Lille, France